Estrogen receptor alpha (ERα) is a common target for breast cancer treatment and is mainly involved in cell proliferation. Breadfruit (Artocarpus altilis) is a well-known traditional herb that has anticancer potential, specifically for inhibiting breast cancer proliferation. This study sought to identify the active compound from breadfruit as a candidate ERα inhibitor. This study used flavonoid compounds as anticancer candidates. Eleven flavonoids compounds were considered, including: cycloaltilisin 7, isocyclomorusin, cyclomorusin, cycloaltilisin, cyclomulberrin, isocyclomulberrin, quercetin, cyclocommunal, artocarpin, artonin E, and morusin. Research was conducted using the exploratory descriptive method. The first step was ligand and receptor preparation before the docking process using VegaZZ. The molecular docking process was calculated using AutoDock Vina in PyRx v.0.8. The docking site was predicted in the inhibitory site of ERα based on the control drug (tamoxifen). Screening for the best docking complex was considered according to highest binding affinity and accurate binding site. The selected compounds were predicted for pharmacokinetics to evaluate the possibility of absorption in the human intestinal tract. The potential of the active drug to pass the membrane was assessed based on the Lipinski rule of five. Finally, the biological process of the best compound was identified using PASS SERVER to explain the accuracy before conducting the experiment in the laboratory. The results suggest that isocyclomorusin had the lowest binding affinity (8.4 kcal/mol) and this compound could act as an anti-neoplastic (Pa > 0.7) towards breast cancer. Isocyclomorusin could be easily absorbed in the human intestine due to an HIA+ score above 1.9 and could pass the bilayer membrane in breast cancer cells because it meets the Lipinski rule of five standard. Based on the results of this study, it appears that isocyclomorusin is a potential candidate for anti- breast cancer treatment derived from Artocarpus altilis that could act as an ERα inhibitor.

1.
O.
Erejuwa
,
S. A.
Sulaiman
and
M. S.
Wahab
,
Molecules
19
,
2497
522
(
2014
).
2.
P. G.
Surtess
,
N. W. J.
Wainwright
,
R. N.
Luben
,
K. T.
Khaw
and
S.A.
Bingham
,
Breast. Cancer Res. Treat.
120
,
169
74
(
2010
).
3.
K.
Matsuo
,
M.
Shimada
,
S.
Yamaguchi
.
Int. J. Cancer
142
,
1022
1032
(
2017
).
4.
J.
Ferlay
,
E.
Steliarova-Foucher
, and
J.
Lortet-Tieulent
,
Eur. J. Cancer
49
,
374
1403
(
2013
).
5.
C.
Diorio
,
J.
Lemieux
,
L.
Provencher
,
J. C.
Hogue
and
E.
Vachon
,
Breast. Cancer. Res. Treat.
136
,
573
579
(
2014
).
7.
Paterni
,
C.
Granchi
,
J. A.
Katzenellenbogen
and
F.
Minutolo
,
Steroids
0
,
13
29
(
2014
).
8.
W. P.
Bocchinfuso
and
K. S.
Korach
,
J. Mammary. Gland. Biol. Neoplasia
2
,
323
334
(
1997
).
9.
J. B.
Gibbs
,
J. Clin. Invest.
105
,
9
13
(
2000
).
10.
E.
Pilar
,
A.
Bosch
,
J.
Perez-Fidalgo
and
A.
Lluch
,
J. CTRV
38
,
698
707
(
2012
).
11.
C. K.
Osborne
,
V.
Bardou
,
T. A.
Hopp
,
G. C.
Chamness
,
S. G.
Hilsenbeck
,
S. A.
Fuqua
,
J.
Wong
,
D. C.
Allred
,
G. M.
Clark
and
R.
Schiff
,
J. Natl. Cancer. Inst.
95
,
353
61
(
2003
).
12.
Y.
Wang
,
K.
Xu
,
L.
Lin
,
Y.
Pan
and
X.
Zheng
X,
Phytochemistry
68
,
1300
1306
(
2007
).
13.
E. T.
Arung
,
B. D.
Wicaksono
,
Y. A.
Handoko
,
I. W.
Kusuma
,
D.
Yulia
and
F.
Sandra
,
Trop. J. Pharm. Res.
4
,
317
324
(
2009
).
14.
W.
Sekarjati
, “
Efek Antikanker Ekstak Etanolik Daun Lavender (Lavandula officinalis Chaix) Terhadap Sel Kanker Payudara T47D Melalui Penekanan Ekspresi Reseptor Estrogen-α
,” Master Thesis,
Sanata Dharma University
,
2014
.
15.
S.
Dallakyan
, and
A. J.
Olson
,
Methods Mol. Biol.
1263
,
243
250
(
2015
).
16.
S. K.
Lee
,
I. H.
Lee
,
H. J.
Kim
,
G. S.
Chang
and
J. E.
Chunf
,
The PreADME Approach: Web-based Program for Rapid Prediction of Physico-Chemical, Drug Absorption and Drug-Like Properties
(
Blackweel Publishing
,
Massachusetts
,
2003
), pp.
418
420
.
17.
C. A.
Lipinski
,
Drug. Discov. Today. Technol
. v
1
,
337
341
(
2004
).
18.
M.A.
Hernandez
MA and
R.
Appu
,
Basic Pharmacology: Understanding Drug Actions and Reaction
(
CRC Press
,
Boca Raton
,
2006
).
19.
K.
Shiau
,
D.
Barstad
,
P. M.
Loria
,
L.
Cheng
,
P. J.
Kushner
,
D. A.
Agard
and
G. L.
Gree
,
Cell
95
,
927
937
(
1998
).
20.
Y
Anita
,
M.
Radifar
,
L. B. S.
Kardono
,
M.
Hanafi
and
E. P.
Istyastono
,
Bioinformation
8
,
901
906
(
2012
).
21.
G.
Nerkar
,
S. A.
Kudale
,
P. P.
Joshi
and
H. U.
hikhale
,
J. Pharm. Pharm. Sci.
4
,
449
453
(
2012
).
22.
M.
Lazzeroni
,
D.
Serrano
,
B. K.
Dunn
,
B. M. H.
Stoddard
,
O.
Lee
,
S.
Khan
and
A.
Decensi
,
Breast. Cancer. Res.
14
,
1
11
(
2012
).
23.
P. B.
Jadhav
,
A. R.
Yadav
and
M. G.
Gore
,
Int. J. Pharma. Bio. Sci.
6
,
142
154
(
2015
).
24.
C. A.
Lipinski
,
F.
Lombardo
,
B. W.
Dominy
and
P. J.
Feeney
,
Adv. Drug. Deliv. Rev.
46
,
3
26
(
2001
).
25.
G.
Patrick
,
Instant Notes in Medicinal Chemistry
(
BIOS Scientific Publisher
,
Oxford
,
2001
).
26.
S
,
Etkins
,
J.
Mestres
, and
B.
Testa
B,
BJMPR.
152
,
21
37
(
2007
)
This content is only available via PDF.